Atlas market file · Equity · United States
Voyager Therapeutics, Inc.VYGR
- Last close
- 3.27
- Change
- +4.47%
- 96-bar range
- 2.94 – 4.46
- As of
- 7 Aug 2026
Voyager Therapeutics, Inc. is a biological products, (no diagnostic substances) issuer listed as VYGR on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
VYGR
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-51.91% over the window).
Source rail: Yahoo Finance chart API (VYGR). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for VYGR. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
VYGR public profile
Biological products, (no diagnostic substances) issuer. Voyager Therapeutics, Inc. is connected to current market context, cited company sources and its retained research file.
Voyager Therapeutics, Inc. trades as VYGR on NASDAQ. Voyager Therapeutics, Inc. (VYGR) has a latest verified close of 3.27, up 4.47%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files VYGR under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for Voyager Therapeutics, Inc. today
Voyager Therapeutics, Inc. has reported a net loss of $27.9M in the quarter ending 2026-03-31, with a significant cash outflow of $33.4M. The company's revenue from contracts with customers was $2.6M, while its research and development expenses were $24.6M.
The company's product, VY1706, has shown promising results in non-human primates, with broad, durable, and dose-dependent CNS delivery. However, the company's financial performance has not yet reflected this progress, with significant cash burn and limited revenue growth.
The company's management team has been actively engaged in buying and selling shares, with multiple 4 filings reported in June 2026. The company's lack of clear guidance on its future revenue growth or profitability may be contributing to the uncertainty surrounding its stock.
The company's cash and cash equivalents have been decreasing, with $43.3M reported in the quarter ending 2026-03-31. The company's ability to sustain its operations without additional funding is a significant concern. The fact that the company has been spending heavily on research and development may be a contributing factor to its cash burn.
Sources & evidence · 9 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
VYGR technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on VYGR
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep VYGR research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
VYGR FAQ
What is Voyager Therapeutics, Inc. (VYGR)?Voyager Therapeutics, Inc. (VYGR) has a latest verified close of 3.27, up 4.47%, dated 7 Aug 2026. Use this page to check the price chart, company context,...
Voyager Therapeutics, Inc. (VYGR) has a latest verified close of 3.27, up 4.47%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for VYGR?Voyager Therapeutics, Inc. (VYGR) has a latest verified close of 3.27, up 4.47%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources,...
Voyager Therapeutics, Inc. (VYGR) has a latest verified close of 3.27, up 4.47%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files VYGR under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the VYGR page updated?The VYGR public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The VYGR public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for VYGR?The VYGR file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:VYGR. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The VYGR file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:VYGR. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on VYGR?Yes. The workstation can open VYGR, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open VYGR, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this VYGR page investment advice?No. The VYGR page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The VYGR page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →